デフォルト表紙
市場調査レポート
商品コード
1714337

流体生検市場- 世界の産業規模、シェア、動向、機会、予測、適応症別、タイプ別、地域別、競合別、2020-2030年

Fluid Biopsy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Indication By Type, By Region, & Competition, 2020-2030F

出版日
ページ情報
英文 182 Pages
納期
2～3営業日
カスタマイズ可能
流体生検市場- 世界の産業規模、シェア、動向、機会、予測、適応症別、タイプ別、地域別、競合別、2020-2030年
出版日: 2025年04月25日
発行: TechSci Research
ページ情報: 英文 182 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

流体生検市場は2024年に118億米ドルと評価され、2030年には227億2,000万米ドルに達し、CAGR 11.50%で成長すると予測されています。

流体生検は、非侵襲的診断における重要な進歩であり、血液、尿、その他の体液中のバイオマーカーの分析を通じて、病気の状態に関するリアルタイムの洞察を提供します。この技術は特に腫瘍学に大きな影響を与え、従来の組織生検を必要とすることなく、がんの早期発見、治療効果のモニタリング、病気の進行の追跡を可能にします。がん罹患率の上昇、精密医療の採用拡大、次世代シーケンシングやデジタルPCRなどの技術進歩が市場の成長を加速させています。流体生検は、出生前検査、感染症検出、遺伝子疾患診断での使用も検討されています。コスト、規制の複雑さ、臨床標準化などの課題にもかかわらず、低侵襲性、幅広い診断用途、個別化治療アプローチによる患者ケアの改善能力により、市場は急速に拡大しています。

市場概要
予測期間 2026-2030
市場規模：2024年 118億米ドル
市場規模：2030年 227億2,000万米ドル
CAGR：2025年～2030年 11.50%
急成長セグメント がん
最大市場 北米

市場促進要因

世界のがん罹患率の上昇

主な市場課題

限定的な臨床検証

主な市場動向

AIおよび機械学習との統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 流体生検市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 適応症別（肺がん、乳がん、大腸がん、その他）
    • タイプ別（循環腫瘍細胞、循環腫瘍DNA、遊離DNA）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米の流体生検市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の流体生検市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域の流体生検市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の流体生検市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの流体生検市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 世界の流体生検市場：SWOT分析

第16章 競合情勢

  • Bio-Rad Laboratories
  • Guardant Health Inc.
  • Illumina, Inc.
  • Qiagen NV
  • Laboratory Corporation of America Holdings
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific Inc.
  • Johnson & Johnso
  • Biocept Inc.
  • Bio-Rad Laboratories, Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

目次
Product Code: 16097

The Fluid Biopsy Market was valued at USD 11.80 billion in 2024 and is projected to reach USD 22.72 billion by 2030, growing at a CAGR of 11.50%. Fluid biopsy represents a significant advancement in non-invasive diagnostics, offering real-time insights into disease status through the analysis of biomarkers in blood, urine, and other body fluids. This technique is particularly impactful in oncology, enabling early cancer detection, monitoring of treatment response, and tracking of disease progression without the need for traditional tissue biopsies. The rise in cancer prevalence, growing adoption of precision medicine, and technological progress-such as next-generation sequencing and digital PCR-are accelerating market growth. Fluid biopsy is also being explored for use in prenatal testing, infectious disease detection, and genetic disorder diagnosis. Despite challenges including cost, regulatory complexity, and clinical standardization, the market is expanding rapidly due to its minimally invasive nature, broad diagnostic applications, and ability to improve patient care through personalized treatment approaches.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 11.80 Billion
Market Size 2030USD 22.72 Billion
CAGR 2025-203011.50%
Fastest Growing SegmentCancer
Largest MarketNorth America

Key Market Drivers

Rising Global Cancer Incidence

The global increase in cancer prevalence is a major factor driving the growth of the fluid biopsy market. With approximately 20 million new cancer cases and 9.7 million related deaths recorded in 2022, and 53.5 million individuals living within five years of a diagnosis, there is a rising need for efficient, non-invasive diagnostic tools. This demand is especially pronounced in aging populations-by 2040, nearly 19.2% of the global population is expected to be over 60, a group disproportionately affected by cancer. Traditional tissue biopsies can be invasive and difficult for certain patients. Fluid biopsy offers a more accessible solution, allowing for early detection through circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs). Furthermore, it supports continuous monitoring, providing insights into disease recurrence and treatment effectiveness. With cancer rates rising globally, fluid biopsy is becoming essential for enhancing early intervention and long-term management, making it a key pillar of modern oncology care.

Key Market Challenges

Limited Clinical Validation

A major challenge for the global fluid biopsy market is the limited clinical validation of its diagnostic technologies. Although fluid biopsy shows great potential, especially in cancer detection and monitoring, many of its assays are still undergoing development and require extensive clinical trials to confirm their sensitivity, specificity, and overall reliability. Without well-established clinical data, healthcare providers may be hesitant to adopt these tests, and regulatory agencies may delay approval. The lack of standardized protocols across institutions also adds complexity. These factors can restrict integration into routine clinical practice. Overcoming this barrier will require significant investments in collaborative research, larger-scale validation studies, and regulatory engagement. Building strong clinical evidence is essential to gaining trust from both physicians and patients and ensuring broader adoption of fluid biopsy technologies in the diagnostic landscape.

Key Market Trends

Integration with AI and Machine Learning

The integration of AI and machine learning is a transformative trend in the fluid biopsy market. These technologies are revolutionizing data analysis by enabling rapid, accurate interpretation of complex biomarker data derived from liquid samples. AI algorithms can detect subtle patterns and correlations that may be missed through traditional analysis, enhancing diagnostic precision and expanding clinical utility. These tools are especially beneficial for early cancer detection, treatment response evaluation, and identifying actionable mutations for targeted therapy. As AI continues to evolve, it enables deeper insights into disease progression and therapeutic outcomes, empowering personalized treatment plans. Additionally, AI can facilitate the discovery of new biomarkers, supporting innovation in diagnostics beyond oncology. By streamlining data processing and improving predictive accuracy, AI integration is solidifying fluid biopsy's role in advancing precision medicine and transforming patient care on a global scale.

Key Market Players

  • Bio-Rad Laboratories
  • Guardant Health Inc.
  • Illumina, Inc.
  • Qiagen NV
  • Laboratory Corporation of America Holdings
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific Inc.
  • Johnson & Johnson
  • Biocept Inc.
  • Bio-Rad Laboratories, Inc.

Report Scope:

In this report, the Global Fluid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fluid Biopsy Market, By Indication:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Other

Fluid Biopsy Market, By Type:

  • Circulating Tumor Cells
  • Circulating Tumor DNA
  • Cell-free DNA

Fluid Biopsy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fluid Biopsy Market.

Available Customizations:

Global Fluid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Fluid Biopsy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Other)
    • 5.2.2. By Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Fluid Biopsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Fluid Biopsy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Type
    • 6.3.2. Canada Fluid Biopsy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Type
    • 6.3.3. Mexico Fluid Biopsy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Type

7. Europe Fluid Biopsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Fluid Biopsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Type
    • 7.3.2. United Kingdom Fluid Biopsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Type
    • 7.3.3. Italy Fluid Biopsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Type
    • 7.3.4. France Fluid Biopsy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Type
    • 7.3.5. Spain Fluid Biopsy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Type

8. Asia-Pacific Fluid Biopsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Type
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Fluid Biopsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Type
    • 8.3.2. India Fluid Biopsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Type
    • 8.3.3. Japan Fluid Biopsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Type
    • 8.3.4. South Korea Fluid Biopsy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Type
    • 8.3.5. Australia Fluid Biopsy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Type

9. South America Fluid Biopsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Type
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Fluid Biopsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Type
    • 9.3.2. Argentina Fluid Biopsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Type
    • 9.3.3. Colombia Fluid Biopsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Type

10. Middle East and Africa Fluid Biopsy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Type
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Fluid Biopsy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Type
    • 10.3.2. Saudi Arabia Fluid Biopsy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Type
    • 10.3.3. UAE Fluid Biopsy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Global Fluid Biopsy Market: SWOT Analysis

16. Competitive Landscape

  • 16.1. Bio-Rad Laboratories
    • 16.1.1. Business Overview
    • 16.1.2. Product & Service Offerings
    • 16.1.3. Recent Developments
    • 16.1.4. Financials (If Listed)
    • 16.1.5. Key Personnel
    • 16.1.6. SWOT Analysis
  • 16.2. Guardant Health Inc.
  • 16.3. Illumina, Inc.
  • 16.4. Qiagen NV
  • 16.5. Laboratory Corporation of America Holdings
  • 16.6. F. Hoffmann-La Roche AG
  • 16.7. Thermo Fisher Scientific Inc.
  • 16.8. Johnson & Johnso
  • 16.9. Biocept Inc.
  • 16.10.Bio-Rad Laboratories, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer